Neosun Biotech (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 18.90%
- Profit Growth 228.52%
- Ebitda 15.87%
- Net Worth 844.32%
- Total Assets 0.19%
About Neosun Biotech (India)
Neosun Biotech (India) Private Limited (NBIPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 December 2005 and has a history of 19 years and one month. Its registered office is in Rangareddy, Telangana, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Anand Gampa, Bandaru Satyanarayana, and Gampa Rani serve as directors at the Company.
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24110TG2005PTC048637
- Company No.
048637
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Dec 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Neosun Biotech (India) Private Limited offer?
Neosun Biotech (India) Private Limited offers a wide range of products and services, including Pharmaceutical Syrup, Oral Suspension, Antibiotic Injection, Tazobactam Injection, Multivitamin Syrup & Drops, Antacid Drugs, Antacid Syrup, Common Disease Medicines, Pharmaceutical Tablets, Antibiotic Tablets & Capsules.
Who are the key members and board of directors at Neosun Biotech (India)?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anand Gampa  | Director | 01-May-2006 | Current |
| Bandaru Satyanarayana | Director | 30-Dec-2005 | Current |
| Gampa Rani | Director | 01-May-2006 | Current |
Financial Performance of Neosun Biotech (India).
Neosun Biotech (India) Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 18.9% increase. The company also saw a substantial improvement in profitability, with a 228.52% increase in profit. The company's net worth Soared by an impressive increase of 844.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neosun Biotech (India)?
In 2021, Neosun Biotech (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Red Bulb Medical Technologies Private LimitedAnand Gampa is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neosun Biotech (India)?
Unlock and access historical data on people associated with Neosun Biotech (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neosun Biotech (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neosun Biotech (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
